Abstract
<p>Supplementary Table S1. Summary of the antibodies used in experiments; Supplementary Table S2. List of compounds confirmed in the high throughput screening with DLD1-R cells; Supplementary Table S3. BECN1 knockdown re-sensitize DLD1-R cells to TRAIL; Supplementary Table S4. IC50 of TRAIL treatment in each cell line; Supplementary Table S5. 17-HW re-sensitizes multiple colon cancer cell lines to TRAIL; Supplementary Table S6. BECN1 knockdown re-sensitize multiple colon cancer cell lines to TRAIL; Supplementary Table S7. Patient demographics and baseline characteristics; Supplementary Table S8. Clinicopathological factors and their relationship to the expression of beclin1 and caspase-8</p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
